{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:45:07Z","timestamp":1766137507860,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007290","name":"Det Obelske Familiefond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Clinical Electrophysiology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jacep.2020.07.005","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T02:30:52Z","timestamp":1598581852000},"page":"1672-1682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease"],"prefix":"10.1016","volume":"6","author":[{"given":"Line","family":"Melgaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thure Filskov","family":"Overvad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben Bjerregaard","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Br\u00f8nnum","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacep.2020.07.005_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","article-title":"Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation","volume":"71","author":"Chao","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2020.07.005_bib2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2020.07.005_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacep.2020.07.005_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.jacep.2020.07.005_bib5","first-page":"22","article-title":"A\u00a0clinical evaluation of atrial fibrillation in rheumatic heart disease","volume":"63","author":"Sharma","year":"2015","journal-title":"J\u00a0Assoc Physicians India"},{"key":"10.1016\/j.jacep.2020.07.005_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0002-9149(97)89145-X","article-title":"Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease","volume":"77","author":"Diker","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacep.2020.07.005_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/europace\/euy151","article-title":"Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating \u201cvalvular heart disease\u201d in a nationwide cohort study","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacep.2020.07.005_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijcard.2018.03.017","article-title":"Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification","volume":"260","author":"Bisson","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacep.2020.07.005_bib9","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/eurheartj\/ehv163","article-title":"Prognostic value of CHA2DS2-VASc score in patients with \u201cnon-valvular atrial fibrillation\u201d and valvular heart disease: the Loire Valley Atrial Fibrillation Project","volume":"36","author":"Philippart","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2020.07.005_bib10","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/europace\/eux240","article-title":"Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis","volume":"19","author":"Lip","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.jacep.2020.07.005_bib11","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2020.07.005_bib12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","article-title":"2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"70","author":"Nishimura","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jacep.2020.07.005_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.jacep.2020.07.005_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.jacep.2020.07.005_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.jacep.2020.07.005_bib16","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","article-title":"Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?","volume":"137","author":"Nielsen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.07.005_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/1403494817716582","article-title":"Predictive value of stroke discharge diagnoses in the Danish National Patient Register","volume":"45","author":"L\u00fchdorf","year":"2017","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.jacep.2020.07.005_bib18","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1160\/TH15-03-0210","article-title":"The risks of risk scores for stroke risk assessment in atrial fibrillation","volume":"113","author":"Nielsen","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacep.2020.07.005_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1536867X0400400201","article-title":"Cumulative incidence estimation in the presence of competing risks","volume":"4","author":"Coviello","year":"2004","journal-title":"Stata J"},{"key":"10.1016\/j.jacep.2020.07.005_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.acvd.2015.06.002","article-title":"How to define valvular atrial fibrillation?","volume":"108","author":"Fauchier","year":"2015","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jacep.2020.07.005_bib21","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/europace\/euu178","article-title":"The definition of valvular and non-valvular atrial fibrillation: results of a physicians\u2019 survey","volume":"16","author":"Molteni","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.jacep.2020.07.005_bib22","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","article-title":"What is \u201cvalvular\u201d atrial fibrillation? A reappraisal","volume":"35","author":"De Caterina","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacep.2020.07.005_bib23","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/europace\/euw302","article-title":"Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of \u2018valvular\u2019 atrial fibrillation: results of the European Heart Rhythm Association Survey","volume":"18","author":"Potpara","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.jacep.2020.07.005_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ehjcvp\/pvz016","volume":"5","author":"Sulzgruber","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacep.2020.07.005_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point","volume":"4","author":"Eckman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacep.2020.07.005_bib26","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1538-7836.2012.04853.x","article-title":"Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study","volume":"10","author":"Mikkelsen","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacep.2020.07.005_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1378\/chest.11-0862","article-title":"Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation","volume":"141","author":"Olesen","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jacep.2020.07.005_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1160\/TH14-06-0545","article-title":"Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation","volume":"112","author":"Overvad","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacep.2020.07.005_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ehjcvp\/pvw022","article-title":"Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score","volume":"3","author":"Overvad","year":"2017","journal-title":"Eur Hear journal Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacep.2020.07.005_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ehjcvp\/pvz039","article-title":"Correspondence: current opinion of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke","volume":"6","author":"Nielsen","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacep.2020.07.005_bib31","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/pds.4793","article-title":"Short lookback periods causing exaggerated stroke risk estimates in atrial fibrillation may expose patients to unnecessary anticoagulant treatment","volume":"28","author":"Friberg","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacep.2020.07.005_bib32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/CIRCULATIONAHA.116.024057","article-title":"Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation","volume":"135","author":"Quinn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacep.2020.07.005_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004580","article-title":"Importance of considering competing risks in time-to-event analyses: application to stroke risk in a retrospective cohort study of elderly patients with atrial fibrillation","volume":"11","author":"Abdel-Qadir","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacep.2020.07.005_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2288-11-83","article-title":"The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients","volume":"11","author":"Thygesen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jacep.2020.07.005_bib35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/14017431.2012.673728","article-title":"Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry","volume":"46","author":"Rix","year":"2012","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.jacep.2020.07.005_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study","volume":"6","author":"Sundb\u00f8ll","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacep.2020.07.005_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135834","article-title":"Validity of diagnostic codes for acute stroke in administrative databases: a systematic review","volume":"10","author":"McCormick","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacep.2020.07.005_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000102143","article-title":"Validity of stroke diagnoses in a National Register of Patients","volume":"28","author":"Krarup","year":"2007","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jacep.2020.07.005_bib39","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"}],"container-title":["JACC: Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X20306046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405500X20306046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:29:01Z","timestamp":1762500541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405500X20306046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":39,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2405500X20306046"],"URL":"https:\/\/doi.org\/10.1016\/j.jacep.2020.07.005","relation":{},"ISSN":["2405-500X"],"issn-type":[{"type":"print","value":"2405-500X"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Clinical Electrophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacep.2020.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}